Skip to main content

Table 1 Clinical characteristics and CGMS parameters

From: Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes

Variables

All (n = 57)

Age (years)

65 ± 12

Male (%)

78.9

Body mass index (kg/m2)

24.2 ± 4.1

STEMI (%)

77.2

Multivessel disease (%)

35.1

Culprit vessel

 Left anterior descending artery (%)

52.6

 Left circumflex coronary artery (%)

14.0

 Right coronary artery (%)

33.3

Current smoking (%)

54.4

Hypertension (%)

61.4

Diabetes mellitus (%)

49.1

Lipid parameters at admission

 Total cholesterol (mg/dl)

201 ± 37

 LDL-C (mg/dl)

128 ± 36

 HDL-C (mg/dl)

46 ± 12

 Triglycerides (mg/dl)

129 ± 96

eGFR at admission (ml/min/1.73 m2)

75.2 ± 18.2

Urinary L-FABP (μg/g creatinine)

20.3 ± 58.0

hs-CRP at 7 days after admission (mg/dl)

1.56 ± 1.72

Medications before admission

 Statin (%)

21.1

 ACEI/ARB (%)

21.1

 Oral anti-diabetic drugs (%)

17.5

Conventional glucose indicators

 HbA1c at admission (%)

6.1 ± 1.0

 FPGa (mg/dl)

109 ± 17

 HOMA-IRa

2.1 ± 1.4

CGMS parametersa

 Maximum blood glucose (mg/dl)

184 ± 48

 Minimum blood glucose (mg/dl)

90 ± 21

 Mean blood glucose (mg/dl)

126 ± 27

 SD around mean blood glucose (mg/dl)

22 ± 12

 MAGE (blood glucose variability) (mg/dl)

48 ± 26

 Hyperglycemia ≥200 mg/dl (%)

29.8

 Hypoglycemia <60 mg/dl (%)

7.0

  1. ACEI/ARB angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blocker, CGMS continuous glucose monitoring system, eGFR estimated glomerular filtration ratio, FPG fasting plasma glucose, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, MAGE mean amplitude of glucose excursion, STEMI ST-segment elevation myocardial infarction, L-FABP liver-type fatty acid-binding protein (in the first morning urine on the day after admission)
  2. aMeasured in a stable condition during hospital admission